赞比亚早期婴儿人类免疫缺陷病毒(HIV)即时诊断的随机试验
在赞比亚6家公立诊所开展实用性试验,将4000名HIV暴露婴儿个体随机分为即时诊断(POC)组与增强标准诊疗(SOC)组,POC组几乎全部当日获得结果而SOC组中位等待27天;POC加快抗逆转录病毒治疗启动,但12个月时存活、在治且病毒抑制的比例两组无显著差异(RR 1.56;95%CI 0.7-3.50)。作者结论认为在集中式早期婴儿诊断运转良好的地区,POC早期婴儿诊断不太可能改善儿童HIV结局。
要点
- POC组几乎全部当日出结果,SOC组中位出结果时间为27天(四分位距22-30天)。
- 81名婴儿确诊HIV,12个月时仅20/81(25%;95%CI 15-34%)存活、在治且病毒抑制。
- POC组13/81(30%;95%CI 16-43%)vs SOC组7/81(19%;95%CI 6-32%),RR 1.56(95%CI 0.7-3.50),无显著差异。
核心结论
- POC早期婴儿诊断消除了诊断延迟并加快抗逆转录病毒治疗启动,但未转化为12个月结局的明确改善。
- 在集中式早期婴儿诊断运转良好的环境中,POC早期婴儿诊断不太可能改善儿童HIV结局。
研究设计与样本
- 在赞比亚6家公立诊所开展的实用性试验,HIV暴露婴儿被个体随机分为POC早期婴儿诊断组(Alere q HIV-1/2 Detect现场检测)或增强标准诊疗早期婴儿诊断组(公共实验室异地检测)。
- 2016年3月至2018年11月共随机4000名HIV暴露婴儿,POC组1989名,SOC组2011名;确诊HIV的婴儿转介抗逆转录病毒治疗并随访12个月。
- 主要结局定义为12个月时存活、在治且病毒抑制。
主要发现
- POC组除2名婴儿外均获得当日结果,SOC组中位出结果时间为27天(四分位距22-30天)。
- 81名(2%;95%CI 1.6-2.5%)婴儿确诊HIV。
- 抗逆转录病毒治疗启动率虽高,但出现15例(19%)死亡、15例(19%)随访丢失和31例(38%)病毒学失败。
- 12个月时仅81名HIV感染婴儿中的20名(25%;95%CI 15-34%)存活、在治且病毒抑制:POC组13名(30%;95%CI 16-43%)vs SOC组7名(19%;95%CI 6-32%),RR 1.56(95%CI 0.7-3.50)。
临床怎么用
- 作者结论认为POC早期婴儿诊断消除了诊断延迟并加快抗逆转录病毒治疗启动,但未带来12个月结局的明确改善。
- 作者认为在集中式早期婴儿诊断运转良好的环境中,POC早期婴儿诊断不太可能改善儿童HIV结局。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Point-of-care (POC) early infant diagnosis (EID) provides same-day results and the potential for immediate initiation of antiretroviral therapy (ART). METHODS: We conducted a pragmatic trial at 6 public clinics in Zambia. HIV-exposed infants were individually randomized to either (1) POC EID (onsite testing with the Alere q HIV-1/2 Detect) or (2) enhanced standard of care (SOC) EID (off-site testing at a public laboratory). Infants with HIV were referred for ART and followed for 12 months. Our primary outcome was defined as alive, in care, and virally suppressed at 12 months. RESULTS: Between March 2016 and November 2018, we randomized 4000 HIV-exposed infants to POC (n=1989) or SOC (n=2011). All but 2 infants in the POC group received same-day results, while the median time to result in the SOC group was 27 (interquartile range: 22-30) days. Eighty-one (2%; 95% confidence interval [CI]: 1.6-2.5%) infants were diagnosed with HIV. Although ART initiation was high, there were 15 (19%) deaths, 15 (19%) follow-up losses, and 31 (38%) virologic failures. By 12 months, only 20 of 81 (25%; 95% CI: 15-34%) infants with HIV were alive, in care, and virally suppressed: 13 (30%; 16-43%) infants in the POC group vs 7 (19%; 6-32%) in the SOC group (RR: 1.56; .7-3.50). CONCLUSIONS: POC EID eliminated diagnostic delays and accelerated ART initiation but did not translate into definitive improvement in 12-month outcomes. In settings where centralized EID is well functioning, POC EID is unlikely to improve pediatric HIV outcomes. CLINICAL TRIALS REGISTRATION: This trial is registered at https://clinicaltrials.gov (NCT02682810).
引用
- Chibwesha CJ, Mollan KR, Ford CE, et al. A Randomized Trial of Point-of-Care Early Infant Human Immunodeficiency Virus (HIV) Diagnosis in Zambia. Clin Infect Dis. 2022. PMID: 34718462. doi:10.1093/cid/ciab923
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。